State University of New York at Buffalo

Climb Bio appoints Douglas E. Williams, Ph.D., as Chair of its Board of Directors, leveraging his 30+ years of biotech leadership experience, including roles at Sana Biotechnology, Codiak BioSciences, and Biogen. Williams' expertise in immunology drug development will support Climb Bio's mission to improve treatments for immune-mediated diseases, focusing on the company's lead candidate, budoprutug.

Early, aggressive treatment of MS brain lesions could prevent faster decline, with higher-dose meds potentially preventing or curing paramagnetic rim lesions (PRLs), linked to rapid deterioration. PRLs, not currently standard in MS diagnosis, should be checked, especially for patients with higher disease activity. Treatments targeting PRLs could reduce MS symptoms by 29% and progression by 19% over five years.